NL-OMON44502尚未招募不适用
ERVE GROWTH FACTOR * MEASUREMENT METHOD VALIDATION STUDY: DRIED BLOOD SPOT ANALYSIS AND SALIVA SAMPLE TESTING COMPARED TO VENOUS SERUM CONCENTRATION - NGF * validation study
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99(—)
入选标准
- •Healthy female and male participants, 18 years or older, who are willing to give informed consent, have sufficient command of Dutch or English language and are capable of understanding participants information.
排除标准
- •- Contraindications for donating blood (phlebitis, dermatitis, psoriasis, lymphedema, arterial venous fistula, hematoma on or around insert place, mamma-amputation or axillary dissection of lymph nodes)
- •- Poor dental condition
- •- Age <18 years
- •- Volunteers who brushed their teeth within 45 minutes prior to saliva sample collection.
- •- Volunteers who had dental work within 24 hours prior to saliva sample collection.
- •- Volunteers who had their last meal, or drank anything except for water within 60 minutes prior to saliva sample collection.
研究者
相似试验
已完成
不适用
An observational study of evaluation method for erythrocyte membrane function. (SWE-2019-08)ot applicableJPRN-UMIN000038348Suntory Wellness Limited40
招募中
1 期
Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.JPRN-jRCT2080225145Pfizer R&D Japan G.K.130
进行中(未招募)
1 期
A Safety, Pharmacokinetic, Pharmacodynamic and Anti-Tumor Study of PF-06873600 in Combination With Endocrine TherapyEUCTR2020-001757-40-BGPfizer Inc.175
进行中(未招募)
2 期
A Study of PF-06873600 in People With CancerJPRN-jRCT2031230326Kawai Norisuke155
招募中
1 期
A phase 1 dose escalating study of ATX-101 given by intravenous infusion once every week in patients with advanced solid tumours.ACTRN12618001070224Therapim Pty Ltd36
